BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29696502)

  • 1. Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.
    Magouliotis DE; Asprodini EK; Svokos KA; Tasiopoulou VS; Svokos AA; Toms SA
    Acta Neurochir (Wien); 2018 Jun; 160(6):1167-1174. PubMed ID: 29696502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
    JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
    Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
    J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
    JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
    Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
    Burri SH; Gondi V; Brown PD; Mehta MP
    Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
    Kesari S; Ram Z;
    CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
    Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
    Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
    JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
    Ballo MT; Conlon P; Lavy-Shahaf G; Kinzel A; Vymazal J; Rulseh AM
    J Neurooncol; 2023 Aug; 164(1):1-9. PubMed ID: 37493865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
    Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
    Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
    Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor treating fields: a novel treatment modality and its use in brain tumors.
    Hottinger AF; Pacheco P; Stupp R
    Neuro Oncol; 2016 Oct; 18(10):1338-49. PubMed ID: 27664860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
    Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
    J Neurooncol; 2024 Jun; 168(2):259-267. PubMed ID: 38563851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
    Riley MM; San P; Lok E; Swanson KD; Wong ET
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
    Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
    Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and Background on Tumor-Treating Fields for Glioblastoma.
    Schwartz MA; Onuselogu L
    Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S20-4. PubMed ID: 27668387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
    Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
    IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.
    Saria MG; Kesari S
    Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S9-S13. PubMed ID: 27668388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.